We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Iq-ai Limited | IQAI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.10 | -5.26% | 1.80 | 08:12:39 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.90 | 1.80 | 1.90 | 1.80 | 1.90 |
| Industry Sector |
|---|
| GENERAL RETAILERS |
| Top Posts |
|---|
Posted at 16/1/2025 09:11 by soulac1 AI for imagery... That's what Iqai has patent for!AI is giving radiologists crisper images with less noise and better analytics, providing a fuller and truer diagnostic picture to inform treatment decisions earlier in the care pathway when a patient's chances for remission and long-term survivability are higher.Deep-learning algorithms are likewise analyzing x-rays, CT scans, and MRI scans to greater effect, using pattern recognition to help detect malignancies and growths potentially missed by the human eye. Researchers are also pairing AI models with specific targeting compounds to help improve diagnostic accuracy. |
Posted at 11/10/2024 16:13 by festario Or he's just dumped a dog stock onto BRH, so he can raise a massive amount of cash at sub 1p on IQAI, Whatever he's up to, it will for his benefit not ours. |
Posted at 11/10/2024 10:00 by howdlep which of course means TB has cash to buy shares in IQAI on the open market or a future placing without going over the 30% and triggering a buyout. Clever |
Posted at 11/10/2024 09:33 by howdlep OK so BRH have bought all the IQAI and FAB shares.N.B. TB/FAB already held 25.15% of #BRH. So they both pocket money from the sale of their IQAI shares but hold a combined 25.15% of the enlarged #BRH |
Posted at 04/7/2024 20:09 by festario Oh great! So using your examples, both of them, the very best we can hope for is between 2p and 2.5p That's if IQAI bucks the trend of the 99.9% of shares that go to zero once they fall below a penny. |
Posted at 27/3/2024 16:39 by bad gateway So's iffy but after recent shenanigans wouldn't be out of place in a sentence with IQAI in it imo. |
Posted at 25/3/2024 16:31 by festario This is no longer selling by brokers, to realise their dodgy fundraising fees, this is PI's throwing their shares on the fire, as they have come to the conclusion that this is worthless now. It probably is, but I suspect that there will be a spike or two along the way, albeit much smaller than in the past, which we can sell in to. All trust seems to have evaporated in IQAI now, and sadly, by association, that includes the directors of IB too. |
Posted at 03/2/2024 13:27 by festario This is a wonderful article for Glioblastoma sufferers, but terrible news for IQAI investors.Basically it looks like Prof Scolyer has developed an immense leap forward in curing this horrific disease, via immunotherapy.Maybe we have backed the wrong horse? https://www.bbc.co.u |
Posted at 31/1/2024 12:11 by howdlep As I say, you do not understand how this works. The FAB holding is no longer included in a IQAI holding RNS because TB is no longer a director of FAB. However, as the Brown family have an interest in FAB, the holding is a 'concert party' interest. If you do not believe me, check with the IQAI corporate advisor.This is why the combined holding cannot go over 30% without an offer being made for the remainder of the shares. |
Posted at 20/8/2023 19:11 by spurs90 #IQAI #stockpick#IQAI On Friday afternoon announced a deal for IB Neuro and IB Delta T1 to be embedded in GE HealthCare's (GEHC) MR Smart Subscription. IB Neuro and IB Delta T1 maps are applications that accept magnetic resonance imaging (MRI) data as input and automatically compute quantitative and proprietary images as output. The global MRI market is projected to grow at a rate of 7% and surpass $11 billion by 2030, and GEHC is a leading player in that market. A factor driving that growth are complementary advancements in imaging software, such as IB's quantitative solutions. Their software is available via the newly launched Bayer Calantic platform. They also have a drug in phase 1 but have already stated it will be entering phase 2 and this will be funded by a partnership with a major pharmaceutical company. They have recently received orphan drug status for this drug for both adult patients and children for the treatment of glioblastoma(brain cancer). They have recently announced they will be starting a second phase 1 study for children and have initiated discussions with several sites who have expressed a collaborative interest. Paediatric brain tumour research and development receive significant philanthropic funding. Consortiums of non-profits exist that help fund clinical trials for children, either partially or in their entirety. #IQAI have already made connections and introduced their progress to one organization. In turn, they identified several hospitals with whom they have established relationships so we should receive an update imminently for this. The ultimate objective of our program is to obtain regulatory approval for a medicine that could offer a positive impact on the length and quality of life for patients who otherwise have no other options. As the trial process continues, their efforts to identify and secure an accelerated regulatory approval pathway will also continue. Pathways, such as Fast Track Designation and Paediatric Rare Disease Priority Review Voucher (PRD-PRV), exist to expedite the development, review, and approval of promising drugs that treat diseases such as GBM and paediatric cancers. Paediatric rare disease priority review vouchers have recently sold for over $100m with examples from Sarepta Therapeutics and bluebird bio both selling theirs to major pharmaceutical companies. #IQAI Also have patented artificial intelligence ("AI") technology, IB Zero G generates enhanced "with contrast" images using only non-contrast (0% gadolinium) images as input. The FDA's response to the FDA 510(k) submission concluded that IB Zero G™ was too novel and unique a product and subsequently directed IB to pursue a different regulatory clearance pathway. IB is compiling additional documentation in preparation for a pre-submission meeting with the FDA and plans to submit a "de novo" application in the second half of the year. The de novo request is a market clearance pathway designed for novel medical devices for which no legally marketed predicate device exists to demonstrate substantial equivalence. So we could receive an update on this imminently also. #IQAI shares have previously traded as high as 24p and as low as 1p with all this recent positive news announced they could in my opinion be headed back to 20p+ although this time they have a dual listing on the us otc market so we could see new all time highs if it gets picked up over there with the us investors having deeper pockets. There are 183m shares in issue and the ceo holds 29% of these so it’s in his best interest for these to succeed. Currently shares are 3.8/4p giving a market capitalisation of £6.9m. With all these factors and with their footprint in the USA only getting bigger and deals being signed better this share will in my opinion be multiples of today’s price in the very near future. #IQAI #stockpick Numbers are end of June.. Cash 90k Income 282k Profit 278k Costs 578k (Admin 572k, Finance 5k etc) Loss 300k Cash used in operations is 224k. More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods and is due, in large part, to the traction gained from our platform partners including TeraRecon (Eureka) and Bayer (Calantic). These partners have the medical expertise and marketing reach to sell our technologies into large existing installed customer bases and have ample sales and marketing resources to win clients. It is a relatively easy up-sell for IB's partners' sales teams to activate IB's technology on platforms already being used clinically. The number of sites evaluating our software continues to increase. Thus, we are optimistic about the revenue activity and anticipate a step-change starting in the 2nd half of 2023. Plus we now have the GE health care network to sell into. GE Health has installed 4 million scanners and other medical devices worldwide. GEHC total assets $28bil. They invest over $1bil annually in R&D. 259k patients supported daily using imaging technology. 2bil patients scanned annually. Lots to look forward to in regards to upcoming updates |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
